UvA-DARE ( Digital Academic Repository ) Neutralizing antibodies to the HIV-1 envelope glycoproteins

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• The antiviral activity of antibodies in vitro and in vivo

  2004cited by this paper
• Immunoglobulin G (IgG) and IgA, but also Nonantibody Factors, Account for In Vitro Neutralization of Human Immunodeficiency Virus (HIV) Type 1 Primary Isolates by Serum and Plasma of HIV-Infected Patients

  2004cited by this paper
• Crystal Structure of a Broadly Neutralizing Anti-HIV-1 Antibody in Complex with a Peptide Mimotope

  2004cited by this paper
• Stability of protein production from recombinant mammalian cells

  2003cited by this paper
• AIDS Vaccines: Back to 'plan A'

  2003cited by this paper
• Heterogeneity of Envelope Molecules Expressed on Primary Human Immunodeficiency Virus Type 1 Particles as Probed by the Binding of Neutralizing and Nonneutralizing Antibodies

  2003cited by this paper
• Fine Mapping of the Interaction of Neutralizing and Nonneutralizing Monoclonal Antibodies with the CD4 Binding Site of Human Immunodeficiency Virus Type 1 gp120

  2003cited by this paper
• Hyperglycosylated Mutants of Human Immunodeficiency Virus (HIV) Type 1 Monomeric gp120 as Novel Antigens for HIV Vaccine Design

  2003cited by this paper
• Peptides Trap the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Fusion Intermediate at Two Sites

  2003cited by this paper
• The Safety, Plasma Pharmacokinetics, and Antiviral Activity of Subcutaneous Enfuvirtide (T-20), a Peptide Inhibitor of gp41-Mediated Virus Fusion, in HIV-Infected Adults

  2002cited by this paper
• A method for the generation of combinatorial antibody libraries using pIX phage display

  2002cited by this paper
• Solid-Phase Proteoliposomes Containing Human Immunodeficiency Virus Envelope Glycoproteins

  2002cited by this paper
• Antibodies, viruses and vaccines

  2002cited by this paper
• Steps toward mapping the human vasculature by phage display

  2002cited by this paper
• The Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2G12 Recognizes a Cluster of α1→2 Mannose Residues on the Outer Face of gp120

  2002cited by this paper
• Antigenic Properties of the Human Immunodeficiency Virus Transmembrane Glycoprotein during Cell-Cell Fusion

  2002cited by this paper
• HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites

  2002cited by this paper
• Genetic analysis of autoantibodies in idiopathic thrombocytopenic purpura reveals evidence of clonal expansion and somatic mutation.

  2002cited by this paper
• Oligomeric and Conformational Properties of a Proteolytically Mature, Disulfide-Stabilized Human Immunodeficiency Virus Type 1 gp140 Envelope Glycoprotein

  2002cited by this paper
• Determination of a Statistically Valid Neutralization Titer in Plasma That Confers Protection against Simian-Human Immunodeficiency Virus Challenge following Passive Transfer of High-Titered Neutralizing Antibodies

  2002cited by this paper
• The Mannose-Dependent Epitope for Neutralizing Antibody 2G12 on Human Immunodeficiency Virus Type 1 Glycoprotein gp120

  2002cited by this paper
• Dissection of Human Immunodeficiency Virus Type 1 Entry with Neutralizing Antibodies to gp41 Fusion Intermediates

  2002cited by this paper
• Highly Stable Trimers Formed by Human Immunodeficiency Virus Type 1 Envelope Glycoproteins Fused with the Trimeric Motif of T4 Bacteriophage Fibritin

  2002cited by this paper
• Mechanisms of viral membrane fusion and its inhibition.

  2001cited by this paper
• Neutralization Synergy of Human Immunodeficiency Virus Type 1 Primary Isolates by Cocktails of Broadly Neutralizing Antibodies

  2001cited by this paper
• Crystal Structure of a Neutralizing Human IgG Against HIV-1: A Template for Vaccine Design

  2001cited by this paper
• Loss of a Single N-Linked Glycan Allows CD4-Independent Human Immunodeficiency Virus Type 1 Infection by Altering the Position of the gp120 V1/V2 Variable Loops

  2001cited by this paper
• A Potent Cross-Clade Neutralizing Human Monoclonal Antibody against a Novel Epitope on gp41 of Human Immunodeficiency Virus Type 1

  2001cited by this paper
• HIV-1 gp41 six-helix bundle formation occurs rapidly after the engagement of gp120 by CXCR4 in the HIV-1 Env-mediated fusion process.

  2001cited by this paper
• Analysis of dominant-negative effects of mutant Env proteins of human immunodeficiency virus type 1.

  2001cited by this paper
• Selection of cell binding and internalizing epidermal growth factor receptor antibodies from a phage display library.

  2001cited by this paper
• Fine Definition of the Epitope on the gp41 Glycoprotein of Human Immunodeficiency Virus Type 1 for the Neutralizing Monoclonal Antibody 2F5

  2001cited by this paper
• An improved procedure for the generation of recombinant single-chain Fv antibody fragments reacting with human CD13 on intact cells

  2001cited by this paper
• gp120: Biologic aspects of structural features.

  2001cited by this paper
• Antigenic Properties of the Human Immunodeficiency Virus Envelope during Cell-Cell Fusion

  2001cited by this paper
• Antibody Protects Macaques against Vaginal Challenge with a Pathogenic R5 Simian/Human Immunodeficiency Virus at Serum Levels Giving Complete Neutralization In Vitro

  2001cited by this paper
• A Recombinant Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Complex Stabilized by an Intermolecular Disulfide Bond between the gp120 and gp41 Subunits Is an Antigenic Mimic of the Trimeric Virion-Associated Structure

  2000cited by this paper
• Membrane Interface-Interacting Sequences within the Ectodomain of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein: Putative Role during Viral Fusion

  2000cited by this paper
• Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates.

  2000cited by this paper
• The role of CD4 and CD8 T cells in recovery and protection from retroviral infection: lessons from the Friend virus model.

  2000cited by this paper
• Paramagnetic proteoliposomes containing a pure, native, and oriented seven-transmembrane segment protein, CCR5

  2000cited by this paper
• Vaccines and the induction of functional antibodies: Time to look beyond the molecules of natural infection?

  2000cited by this paper
• Oligomeric Modeling and Electrostatic Analysis of the gp120 Envelope Glycoprotein of Human Immunodeficiency Virus

  2000cited by this paper
• Selection of tumor-specific internalizing human antibodies from phage libraries.

  2000cited by this paper
• Evidence That the Transition of HIV-1 Gp41 into a Six-Helix Bundle, Not the Bundle Configuration, Induces Membrane Fusion

  2000cited by this paper
• The pre‐transmembrane region of the human immunodeficiency virus type‐1 glycoprotein: a novel fusogenic sequence

  2000cited by this paper
• New targets for inhibitors of HIV-1 replication

  2000cited by this paper
• Recognition properties of V3-specific antibodies to V3 loop peptides derived from HIV-1 gp120 presented in multiple conformations.

  2000cited by this paper
• Generation and Structural Analysis of Soluble Oligomeric gp140 Envelope Proteins Derived from Neutralization-Resistant and Neutralization-Susceptible Primary HIV Type 1 Isolates

  2000cited by this paper
• V2 Loop Glycosylation of the Human Immunodeficiency Virus Type 1 SF162 Envelope Facilitates Interaction of This Protein with CD4 and CCR5 Receptors and Protects the Virus from Neutralization by Anti-V3 Loop and Anti-CD4 Binding Site Antibodies

  2000cited by this paper
• Sequential CD4-Coreceptor Interactions in Human Immunodeficiency Virus Type 1 Env Function: Soluble CD4 Activates Env for Coreceptor-Dependent Fusion and Reveals Blocking Activities of Antibodies against Cryptic Conserved Epitopes on gp120

  2000cited by this paper
• Variable-Loop-Deleted Variants of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Can Be Stabilized by an Intermolecular Disulfide Bond between the gp120 and gp41 Subunits

  2000cited by this paper
• In vivo selection of sFv from phage display libraries.

  2000cited by this paper
• Natural and designer binding sites made by phage display technology.

  2000cited by this paper
• Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein.

  2000cited by this paper
• Insights into a Structure-Based Mechanism of Viral Membrane Fusion

  2000cited by this paper
• Characterization of Murine Coronavirus Neutralization Epitopes with Phage-Displayed Peptides

  2000cited by this paper
• Fine definition of a conserved CCR5-binding region on the human immunodeficiency virus type 1 glycoprotein 120.

  2000cited by this paper
• Expression and Characterization of a Single-Chain Polypeptide Analogue of the Human Immunodeficiency Virus Type 1 gp120-CD4 Receptor Complex

  2000cited by this paper
• Beyond receptor expression: the influence of receptor conformation, density, and affinity in HIV-1 infection.

  2000cited by this paper
• Energetics of the HIV gp120-CD4 binding reaction.

  2000cited by this paper
• Ubiquitination of the Human Immunodeficiency Virus Type 1 Env Glycoprotein

  2000cited by this paper
• A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1

  2000cited by this paper
• Recognition by Human Monoclonal Antibodies of Free and Complexed Peptides Representing the Prefusogenic and Fusogenic Forms of Human Immunodeficiency Virus Type 1 gp41

  2000cited by this paper
• Requirement for multiple lymphocyte subsets in protection by a live attenuated vaccine against retroviral infection

  1999cited by this paper
• Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein.

  1999cited by this paper
• HIV vaccines. Magic of the occult?

  1999cited by this paper
• Identification of a human anti-CD55 single-chain Fv by subtractive panning of a phage library using tumor and nontumor cell lines.

  1999cited by this paper
• Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein.

  1999cited by this paper
• Role of the Membrane-Proximal Domain in the Initial Stages of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein-Mediated Membrane Fusion

  1999cited by this paper
• Expression and Characterization of HIV Type 1 Envelope Protein Associated with a Broadly Reactive Neutralizing Antibody Response

  1999cited by this paper
• Fusion-competent vaccines: broad neutralization of primary isolates of HIV.

  1999cited by this paper
• Processing and routage of HIV glycoproteins by furin to the cell surface.

  1999cited by this paper
• Phage antibodies against human dendritic cell subpopulations obtained by flow cytometry-based selection on freshly isolated cells.

  1999cited by this paper
• Protection of Macaques against Pathogenic Simian/Human Immunodeficiency Virus 89.6PD by Passive Transfer of Neutralizing Antibodies

  1999cited by this paper
• Stoichiometry of Monoclonal Antibody Neutralization of T-Cell Line-Adapted Human Immunodeficiency Virus Type 1

  1999cited by this paper
• Recombinant human monoclonal antibodies to Ebola virus.

  1999cited by this paper
• A Conserved Tryptophan-Rich Motif in the Membrane-Proximal Region of the Human Immunodeficiency Virus Type 1 gp41 Ectodomain Is Important for Env-Mediated Fusion and Virus Infectivity

  1999cited by this paper
• Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine

  1999cited by this paper
• Protection by Live, Attenuated Simian Immunodeficiency Virus against Heterologous Challenge

  1999cited by this paper
• Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo.

  1999cited by this paper
• Cross-Subtype Neutralizing Antibodies Induced in Baboons by a Subtype E gp120 Immunogen Based on an R5 Primary Human Immunodeficiency Virus Type 1 Envelope

  1999cited by this paper
• Crystal structure of the two N-terminal domains of g3p from filamentous phage fd at 1.9 A: evidence for conformational lability.

  1999cited by this paper
• Probability Analysis of Variational Crystallization and Its Application to gp120, The Exterior Envelope Glycoprotein of Type 1 Human Immunodeficiency Virus (HIV-1)*

  1999cited by this paper
• Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques

  1999cited by this paper
• Ebola Virus Can Be Effectively Neutralized by Antibody Produced in Natural Human Infection

  1999cited by this paper
• Neutralizing antibody directed against the HIV–1 envelope glycoprotein can completely block HIV–1/SIV chimeric virus infections of macaque monkeys

  1999cited by this paper
• Kinetics of the Development of Protective Immunity in Mice Vaccinated with a Live Attenuated Retrovirus

  1999cited by this paper
• HIV-1 entry inhibitors in the side pocket.

  1999cited by this paper
• Constitutive cell surface association between CD4 and CCR5.

  1999cited by this paper
• Selection-dominant and nonaccessible epitopes on cell-surface receptors revealed by cell-panning with a large phage antibody library.

  1999cited by this paper
• Resistance to HIV-1 infection among highly exposed sex workers in Nairobi: what mediates protection and why does it develop?

  1999cited by this paper
• Enhanced Expression, Native Purification, and Characterization of CCR5, a Principal HIV-1 Coreceptor*

  1999cited by this paper
• A sensitive immunoassay for rat fatty acid translocase (CD36) using phage antibodies selected on cell transfectants: abundant presence of fatty acid translocase/CD36 in cardiac and red skeletal muscle and up-regulation in diabetes.

  1999cited by this paper
• HIV–1 neutralizing antibodies: How full is the bottle?

  1999cited by this paper
• Model systems to study the parameters determining the success of phage antibody selections on complex antigens.

  1999cited by this paper
• The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity.

  1999cited by this paper
• Antibody Neutralization-Resistant Primary Isolates of Human Immunodeficiency Virus Type 1

  1998cited by this paper
• A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding.

  1998cited by this paper
• Effects of CCR5 and CD4 Cell Surface Concentrations on Infections by Macrophagetropic Isolates of Human Immunodeficiency Virus Type 1

  1998cited by this paper

• Uses and Challenges of Antiviral Polyclonal and Monoclonal Antibody Therapies

  2023cites this paper
• Engineered CD4 T cells expressing a membrane anchored viral inhibitor restrict HIV-1 through cis and trans mechanisms

  2023cites this paper
• Across Functional Boundaries: Making Nonneutralizing Antibodies To Neutralize HIV-1 and Mediate Fc-Mediated Effector Killing of Infected Cells

  2021cites this paper
• Across functional boundaries: making non-neutralizing antibodies to neutralize HIV-1 and mediate Fc-mediated effector killing of infected cells

  2021cites this paper
• Phage display as a tool for identifying HIV-1 broadly neutralizing antibodies

  2021influential citation
• HIV Vaccine Development: The Importance of Gp120 Variable loop 3 for the survival of the Human Immunodeficiency Virus and the Potency of the Neutralizing Antibody to bind to the Variable Loop 3

  2020cites this paper
• Defining rules governing recognition and Fc-mediated effector functions to the HIV-1 co-receptor binding site

  2020cites this paper
• HIV-1 neutralisierende Antikörper als Werkzeuge für prophylaktische und therapeutische Impfansätze

  2020cites this paper
• Glycosyl-Phosphatidylinositol-Anchored Anti-HIV Env Single-Chain Variable Fragments Interfere with HIV-1 Env Processing and Viral Infectivity

  2018cites this paper
• FIV vaccine with receptor epitopes results in neutralizing antibodies but does not confer resistance to challenge

  2018cites this paper
• m3-aa scFv VITQSPG'ELS LSAGERAILS CRASQSVSSG SLAWYQQKPG QAPRILIYGA X5-aa scFv VITQSPGTES ISAGERATIS CRASQSVSSG SLAWYQQKPG QAPRILLIYGA mó-aa scFv VLTQSPGELS LSAGERATIS CRASQSVSSG SLAWYQQKPG QAPRLLIYGA

  2017cites this paper
• Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates

  2017cites this paper
• Single N277A substitution in C2 of simian immunodeficiency virus envelope influences vaccine-elicited CD4i neutralizing and anti-V2 antibody responses.

  2017cites this paper
• Lessons learned from humoral responses of HIV patients

  2017cites this paper
• Comparison of Antibody-Dependent Cell-Mediated Cytotoxicity and Virus Neutralization by HIV-1 Env-Specific Monoclonal Antibodies

  2016cites this paper
• HIV-1-Specific Chimeric Antigen Receptors Based on Broadly Neutralizing Antibodies

  2016cites this paper
• HIV-1-Specific Chimeric Antigen Receptors Based on 1 Broadly-Neutralizing Antibodies 2 3 ( Running Title : Novel HIV-1-Specific bnAb CARs ) 4 5

  2016cites this paper
• Glycosylphosphatidylinositol-Anchored Anti-HIV scFv Efficiently Protects CD4 T Cells from HIV-1 Infection and Deletion in hu-PBL Mice

  2016cites this paper
• HbAHP-25, an In-Silico Designed Peptide, Inhibits HIV-1 Entry by Blocking gp120 Binding to CD4 Receptor

  2015cites this paper
• Stability engineering of anti-EGFR scFv antibodies by rational design of a lambda-to-kappa swap of the VL framework using a structure-guided approach

  2015cites this paper
• Complementary and synergistic activities of anti-V3, CD4bs and CD4i antibodies derived from a single individual can cover a wide range of HIV-1 strains.

  2015cites this paper
• Gp120/CD4 Blocking Antibodies Are Frequently Elicited in ART-Naïve Chronically HIV-1 Infected Individuals

  2015cites this paper
• N-terminal residues of an HIV-1 gp41 membrane-proximal external region antigen influence broadly neutralizing 2F5-like antibodies

  2015influential citation
• Specific sequences commonly found in the V3 domain of HIV-1 subtype C isolates affect the overall conformation of native Env and induce a neutralization-resistant phenotype independent of V1/V2 masking.

  2014cites this paper
• Engineered Antibody Domains as Candidate Therapeutics

  2014cites this paper
• Passive Immunization against HIV/AIDS by Antibody Gene Transfer

  2014cites this paper
• Neutralisation of HIV-1 cell-cell spread by human and llama antibodies

  2014cites this paper
• Epitope Mapping of M36, a Human Antibody Domain with Potent and Broad HIV-1 Inhibitory Activity

  2013cites this paper
• Increased Functional Stability and Homogeneity of Viral Envelope Spikes through Directed Evolution

  2013influential citation
• Impact of IgA Constant Domain on HIV-1 Neutralizing Function of Monoclonal Antibody F425A1g8

  2013cites this paper
• Développement d'anticorps monoclonaux humains de type IgA dirigés contre la partie C-terminale de la protéine d'enveloppe gp41 du VIH-1

  2013cites this paper
• Neutralizing antibodies to HIV-1 induced by immunization

  2013cites this paper
• Engineering of HIV gp120 by yeast surface display for neutralizing antibody characterization and immunogen design

  2013influential citation
• A Modern Biopharmaceutical to Treat AIDS – Challenges in Designing HIV Env Immunogens for Developing a Vaccine

  2013cites this paper
• Profiling the IgOme: Meeting the challenge

  2013cites this paper
• Engineered antibody variable and constant domains as therapeutic candidates.

  2013cites this paper
• Preventive and therapeutic applications of neutralizing antibodies to Human Immunodeficiency Virus Type 1 (HIV-1)

  2013cites this paper
• Prime-Boost Immunization of Rabbits with HIV-1 gp120 Elicits Potent Neutralization Activity against a Primary Viral Isolate

  2013cites this paper
• The potential of the human immune system to develop broadly neutralizing HIV-1 antibodies: implications for vaccine development

  2013cites this paper
• Neutralizing Antibody Responses in Macaques Induced by Human Immunodeficiency Virus Type 1 Monovalent or Trivalent Envelope Glycoproteins

  2013cites this paper
• Broadly Neutralizing Antibodies Developed by an HIV-Positive Elite Neutralizer Exact a Replication Fitness Cost on the Contemporaneous Virus

  2012cites this paper
• Defining C3-V4 neutralisation epitopes on human immunodeficiency virus type-1 subtype c envelope glycoproteins

  2012cites this paper
• Antibody Neutralizing Function of Monoclonal Impact of IgA Constant Domain on HIV-1

  2012cites this paper
• Rapid conformational epitope mapping of anti-gp120 antibodies with a designed mutant panel displayed on yeast.

  2012cites this paper
• Isolation of HIV-1-Neutralizing Mucosal Monoclonal Antibodies from Human Colostrum

  2012cites this paper
• Selection of antibodies from synthetic antibody libraries.

  2012cites this paper
• A novel strategy for efficient production of anti-V3 human scFvs against HIV-1 clade C

  2012cites this paper
• Role of Human Immunodeficiency Virus Type 1 Envelope Structure in the Induction of Broadly Neutralizing Antibodies

  2012cites this paper
• Phages and HIV-1: From Display to Interplay

  2012cites this paper
• Candidate Antibody-Based Therapeutics Against HIV-1

  2012cites this paper
• Straightforward selection of broadly neutralizing single-domain antibodies targeting the conserved CD4 and co-receptor binding sites of HIV-1 gp120

  2012cites this paper
• A Monoclonal Antibody Directed against a Conformational Epitope of the HIV-1 Trans-activator (Tat) Protein Neutralizes Cross-clade

  2012cites this paper
• Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding

  2012cites this paper
• Etablierung eines lentiviralen Display-Systems mit Hilfe eines auf einer HI-viralen Verpackungszelllinie basierenden Vektorsystems: Proof of concept anhand des HIV-1 Hüllproteins

  2011cites this paper
• Potent and Broad Anti-HIV-1 Activity Exhibited by a Glycosyl-Phosphatidylinositol-Anchored Peptide Derived from the CDR H3 of Broadly Neutralizing Antibody PG16

  2011cites this paper
• Broad-Spectrum Inhibition of HIV-1 by a Monoclonal Antibody Directed against a gp120-Induced Epitope of CD4

  2011cites this paper
• Nanobodies®: new ammunition to battle viruses.

  2011cites this paper
• Molecular and Functional Properties of Transmitted HIV-1 Envelope Variants: A Dissertation

  2011cites this paper
• Designing Immunogens for Vaccine Development in Reference to HIV

  2011cites this paper
• Structural Characterization of the anti-HIV-1 Broadly Neutralizing Monoclonal Antibody 2F5

  2011cites this paper
• Identification of potential epitopes for the design of HIV-1 vaccine in Kenya

  2011cites this paper
• Bifunctional fusion proteins of the human engineered antibody domain m36 with human soluble CD4 are potent inhibitors of diverse HIV-1 isolates.

  2010cites this paper
• Stabilized HIV-1 Envelope Glycoprotein Trimers Lacking the V1V2 Domain, Obtained by Virus Evolution*

  2010cites this paper
• Potent and broad neutralizing activity of a single chain antibody fragment against cell-free and cell-associated HIV-1

  2010cites this paper
• Inhibition of HIV‐1 Entry: Multiple Keys to Close the Door

  2010cites this paper
• Surface plasmon resonance for vaccine design and efficacy studies: recent applications and future trends

  2010cites this paper
• HIV-1 neutralizing humoral immunity, viral evolution and disease progression

  2010cites this paper
• A Strategy for Eliciting Antibodies against Cryptic, Conserved, Conformationally Dependent Epitopes of HIV Envelope Glycoprotein

  2010cites this paper
• STUDIES TO UNDERSTAND THE MECHANISM OF HORIZONTAL AND VERTICAL TRANSMISSION OF HUMAN IMMUNODEFICIENCY VIRUS

  2010cites this paper
• Broader HIV-1 neutralizing antibody responses induced by envelope glycoprotein mutants based on the EIAV attenuated vaccine

  2010cites this paper
• Feline immunodeficiency virus (FIV) as a model for study of lentivirus infections: parallels with HIV.

  2010cites this paper
• Modelling the Evolution of HIV-1 Protein-Coding Sequences with Particular focus on the early stages of Infection

  2010cites this paper
• The role of virus neutralisation in immunity to feline immunodeficiency virus infection

  2010cites this paper
• In-Solution Virus Capture Assay Helps Deconstruct Heterogeneous Antibody Recognition of Human Immunodeficiency Virus Type 1

  2010cites this paper
• A Limited Number of Antibody Specificities Mediate Broad and Potent Serum Neutralization in Selected HIV-1 Infected Individuals

  2010cites this paper
• Role of Complex Carbohydrates in Human Immunodeficiency Virus Type 1 Infection and Resistance to Antibody Neutralization (cid:1)

  2010cites this paper
• Polyvalent AIDS vaccines.

  2010cites this paper
• Emerging studies of human HIV-specific antibody repertoires.

  2010cites this paper
• Structure–function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design

  2010cites this paper
• GPI-anchored single chain Fv - an effective way to capture transiently-exposed neutralization epitopes on HIV-1 envelope spike

  2010influential citation
• Variations in autologous neutralization and CD4 dependence of b12 resistant HIV-1 clade C env clones obtained at different time points from antiretroviral naïve Indian patients with recent infection

  2010cites this paper
• Role of Complex Carbohydrates in Human Immunodeficiency Virus Type 1 Infection and Resistance to Antibody Neutralization

  2010cites this paper
• Cross-Reactive Human IgM-Derived Monoclonal Antibodies that Bind to HIV-1 Envelope Glycoproteins

  2010cites this paper
• Selection of full‐length IgGs by tandem display on filamentous phage particles and Escherichia coli fluorescence‐activated cell sorting screening

  2010cites this paper
• Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology

  2010cites this paper
• The role of antibodies in HIV vaccines.

  2010cites this paper
• Title Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins : Implications for evasion of immune responses and design of vaccine

  2009cites this paper
• Therapeutic Antibodies

  2009cites this paper
• Maturation Pathways of Cross-Reactive HIV-1 Neutralizing Antibodies

  2009cites this paper
• Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41

  2009cites this paper
• Broadly Reactive Monoclonal Antibodies to Multiple HIV-1 Subtype and SIVcpz Envelope Glycoproteins

  2009cites this paper
• Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: Implications for evasion of immune responses and design of vaccine immunogens

  2009cites this paper
• Human monoclonal antibodies and engineered antibody domains as HIV-1 entry inhibitors

  2009cites this paper
• Libraries against libraries for combinatorial selection of replicating antigen–antibody pairs

  2009cites this paper
• Germline-like predecessors of antibodies Implications for evasion of immune responses and design of vaccine immunogens

  2009cites this paper
• Characterisation of llama antibody fragments able to act as HIV-1 entry inhibitors

  2009cites this paper
• Design, expression, and characterization of a multivalent, combination HIV microbicide

  2009cites this paper
• A large library based on a novel (CH2) scaffold: identification of HIV-1 inhibitors.

  2009cites this paper
• Neutralization of HIV by antibodies.

  2009cites this paper
• HIV-1/SIV Neutralizing Antibody Gene Delivery: A Novel Vaccination Approach

  2009cites this paper